Home Newsfeeds GT Biopharma Q2 EPS $(0.10) Up From $(0.15) YoY

GT Biopharma Q2 EPS $(0.10) Up From $(0.15) YoY

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.

byBenzinga Newsdesk

August 11, 2022

1 minute read

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.10) per share. This is a 33.33 percent increase over losses of $(0.15) per share from the same period last year.

Sega Reevaluates Blockchain Strategy: COO Calls ‘Play-To-Earn Games Are Boring’

By Franca Quarneti

July 7, 2:00 PM

Sega Corp. (OTC: SGAMY) the Japanese video game company behind "Sonic The Hedgehog," is re-evaluating its position in the blockchain gaming sector following the recent downturn in the global cryptocurrency market.

NCBDF

Coeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offering

By Benzinga Newsdesk

June 14, 9:30 AM

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering

COEP

Horizon Therapeutics Plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be presented At ECTRIMS 2023

By Benzinga Newsdesk

October 2, 8:14 AM

-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses --Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at the

HZNP

Pilgrims Pride Q3 Adj. EPS $1.09 Beats $0.86 Estimate, Sales $4.47B Beat $4.43B Estimate

By Michael Horton

October 26, 4:34 PM

Pilgrims Pride (NASDAQ:PPC) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.86 by 26.74 percent. This is a 62.69 percent increase over earnings of $0.67 per share from the

PPC

GT Biopharma Q2 EPS $(0.10) Up From $(0.15) YoY

Related Posts

Sega Reevaluates Blockchain Strategy: COO Calls ‘Play-To-Earn Games Are Boring’

Coeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offering

Horizon Therapeutics Plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be presented At ECTRIMS 2023

Pilgrims Pride Q3 Adj. EPS $1.09 Beats $0.86 Estimate, Sales $4.47B Beat $4.43B Estimate